drugset / Trial / NCT00098124

Study of Milnacipran for the Treatment of Fibromyalgia

NCT00098124

Phase 3 Completed 1200 enrolled Forest Laboratories
RandomizedParallel-groupDouble-blindTreatment

Summary

Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.

Timeline

Start
2004-11
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Milnacipran Other / unclassified 100 mg
Subject Milnacipran Other / unclassified 200 mg

Indications